N-[3-[1-[6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: N-[3-[1-[6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
• 化学式: C₃₁H₃₃F₃N₂O₅S
• 分子量: 602.7
• InChiKey: NZPXPXAGXYTROM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  42
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
  申请人：Abbott GmbH & Co. KG

  公开号：EP1880715A1

  公开（公告）日：2008-01-23

  A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake.

  本发明公开了一种药学上可接受的增溶组合物，它包含(i)至少一种具有聚亚烷基二醇分子的生育酚化合物和(ii)至少一种亚烷基二醇脂肪酸单酯或亚烷基二醇脂肪酸单酯和二酯的混合物。该增溶组合物可用于制造药物剂型，该剂型包括至少一种活性成分和至少一种药学上可接受的聚合物的熔融加工混合物。活性成分可以是 HIV 蛋白酶抑制剂。增溶组合物提高了口服后活性成分的生物利用度。
• PHARMACEUTICAL DOSAGE FORM CONTAINING PHARMACEUTICALLY ACCEPTABLE SOLUBILIZING COMPOSITION
  申请人：AbbVie Deutschland GmbH & Co KG

  公开号：EP2046298B1

  公开（公告）日：2016-11-30
• PHARMACEUTICALLY ACCEPTABLE SOLUBILIZING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING SAME
  申请人：Abbott GmbH & Co. KG

  公开号：EP2046298A1

  公开（公告）日：2009-04-15
• Pharmaceutically Acceptable Solubilizing Composition and Pharmaceutical Dosage Form Containing Same
  申请人：ABBVIE DEUTSCHLAND GMBH & CO KG

  公开号：US20150314000A1

  公开（公告）日：2015-11-05

  Pharmaceutically acceptable solubilizing compositions comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester are disclosed. The solubilizing compositions are useful in the manufacture of pharmaceutical dosage forms comprising a melt-processed mixture of at least one active ingredient and at least one pharmaceutically acceptable polymer. The solubilizing compositions enhance the bioavailability of the active ingredient following oral intake.
• US9078921B2
  申请人：——

  公开号：US9078921B2

  公开（公告）日：2015-07-14